|
Canada-0-SCALES Azienda Directories
|
Azienda News:
- Driving Co-Development of Therapeutic Drugs and Companion Diagnostics
Development of companion diagnostics (CDx) as powerful tools in precision medicine typically follows one of three pathways: co-development, bridging, and follow-on Co-development is the most ideal and cost-effective CDx pathway: It is conducive to screening target patients specifically and identifying drug targets accurately, reducing development cost and cycle times for pharmaceutical
- Are Liquid Biopsies the Future of Cancer Biomarkers in Diagnosis or . . .
The Current Status for HER2 Testing There is a large portfolio of available human epidermal growth factor receptor 2 (HER2)-targeted therapies that have an associated companion diagnostic (CDx) in breast and gastric cancers which confirms ERBB2 amplification status (i e , HER2 gene amplification) and or HER2 protein overexpression on the surface of tumor cells These include drugs such as
- Ideas Shaping Innovation: Global Forum and TIRS Top Ten from 2025
Turning the corner on 2026’s first calendar quarter presents a good opportunity to revisit the top ten, most-read Global Forum articles from 2025
- China Focusing Innovation Through ICH Global Regulatory Vision
As these national guidelines and regulations continue to create favorable conditions for development of drug-CDx reagents in China, industry has responded with calls for China’s companion diagnostic products regulation to keep pace with drug regulation reform, to learn from advanced regulatory systems like those in Europe and the US, and for
- FOR SALE - Visalia-Tulare, CA - Page 40,764 - JLA FORUMS
Things for sale in the Visalia and Tulare County area of California - Page 40,764
- Conversations in ASEAN: Facilitating Access to Precision Medicine, and . . .
Integral to PM are companion diagnostics (CDx), devices designed and developed to select the right patient candidates for the precision drug Inevitably, this codependent relationship between drug and device flags the need for tight coordination of the development and regulatory review of both products to ensure timely access to PM CDx
- The EU AI Regulation: Transforming Clinical Research Through Regulation
In an era where artificial intelligence (AI) is revolutionizing healthcare and clinical research, regulatory bodies are racing to keep pace
- Regulatory Opportunities for Decentralized Clinical Trials: Insights . . .
Clinical trials generate evidence that ultimately defines the safety and efficacy of a new medical product
- China’s Evolving Role: From Harmonization to Source of Innovative . . .
In the rapidly evolving global pharmaceutical research and development landscape, China is transitioning from harmonization with international standards to becoming a vital innovation engine
- Why Do Sponsors and CROs Need a Trade Association Dedicated to . . .
The clinical trial ecosystem has become increasingly complex, with the number of drugs in development nearly doubling between 2012 and 2022
|
|